RLAY (Relay Therapeutics) Moat Score: 4/10 (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RLAY Relay Therapeutics Inc RLAY
53 GF Score
Price $19.95
GF Value $3.80
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Relay Therapeutics Moat Score?

Relay Therapeutics RLAY -0.67% 53 Moat Score is 4 as of Aug. 13, 2026. GuruFocus rates RLAY with a GF Score™ of 53/100 and a GF Value™ of $3.80 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,388 Biotechnology companies, Relay Therapeutics ranks better than 88.76% on this metric.

Relay Therapeutics has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Relay Therapeutics has Narrow Moat: Relay Therapeutics Inc has a discernible but modest moat due to its valuable intellectual property and R&D capabilities. However, it lacks strong market leadership, brand strength, and significant regulatory barriers, limiting its competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Relay Therapeutics might have Narrow Moat - Discernible but modest moat.

Relay Therapeutics  (NAS:RLAY) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Relay Therapeutics Moat Score Related Terms

RLAY vs CELC, VKTX, DYN: Moat Score Comparison

For the Biotechnology subindustry, Relay Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Relay Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relay Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Relay Therapeutics's Moat Score falls into.


RLAY
53GF Score
Relay Therapeutics Inc RLAY
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Relay Therapeutics (RLAY) has a Moat Score of 4 as of Aug. 13, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Relay Therapeutics ranks #156 out of 1388 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Relay Therapeutics' Moat Score too high?
Relay Therapeutics' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Relay Therapeutics' value of 4 is 100% above this industry median. Based on the distribution chart, Relay Therapeutics ranks #156 out of 1388 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Relay Therapeutics has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Relay Therapeutics' Moat Score compare to CELC and VKTX?
According to the Biotechnology industry distribution chart, Relay Therapeutics ranks #156 out of 1388 companies for Moat Score. This places Relay Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Relay Therapeutics' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,388 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Relay Therapeutics's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Relay Therapeutics's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relay Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Relay Therapeutics (RLAY) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.80, compared to a current price of $19.95 — trading 424.9% above its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Relay Therapeutics' overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Relay Therapeutics (RLAY), the current Moat Score is 4 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Relay Therapeutics (RLAY) Overvalued in 2026?

Based on GuruFocus' analysis, Relay Therapeutics stock appears to be overvalued. The current stock price of $19.95 is trading 424.9% above its estimated GF Value™ of $3.80. GuruFocus considers Relay Therapeutics to be Significantly Overvalued.

Key valuation signals for RLAY:

  • Moat Score: 4
  • GF Value™: $3.80 vs. price of $19.95 (424.9% above fair value)
  • GF Score™: 53/100 with 7 warning signs
  • Industry Position: 100% above the Biotechnology median (#156 of 1388)

No single metric tells the full story. See the RLAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Relay Therapeutics Business Description

Address 60 Hampshire Street, Cambridge, MA, USA, 02139
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
53GF Score

Get the complete analysis for RLAY

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.95
Price
$3.80
GF Value